Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
The trademark rights for these brands will be transferred to Lupin by March next year.
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
This product will be manufactured at Lupin’s Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated
